Lupin has launched 10 products in the US this fiscal year and has received approvals for 21 from the FDA. The drug maker has 35 FTF product...

From a joiner to a senior, everyone at Amex must go through a continuous development program under a leader, mentor and sponsor.

Indian generic drug producers are devising fresh strategies to continue benefiting from the world’s largest pharmaceutical market the Unite...

The scheme will invest 65%-95% of assets in debt securities, another 0-30% in money market securities and 5%-20% in equities.

Morgan Stanley has rated Sun Pharmaceutical Industries an 'overweight' after the US Supreme Court ruled in favor of Caraco in the Prandin c...

"The FDA has been very positive about Ranbaxy's intent to launch the product and we are working towards meeting the launch timeline", a per...

A successful approval for Aricept should improve investor confidence in Ranbaxy’s ability to convert its FTF applications.

HDFC Securities has downgraded Ranbaxy Laboratories (RLL) from Hold to “Sell” with a price target of Rs 230 per share in its post-result up...

Given the attractive valuations at current levels, Reliance Money has upgraded its rating on Ranbaxy Laboratories from ‘hold’ to ‘buy’ with...

Foreign brokerages have downgraded Ranbaxy Laboratories after the US FDA (Food and Drug Administration) recently invoked its Application In...

Given the twin uncertainties of the continued US FDA import ban and potential currency exchange losses, JP Morgan remains 'Neutral ' on Ran...

Ranbaxy may shift production of the $1.5-billion drug Valacyclovir to its other FDA- approved facilities. The Top 10 food myths revealed | ...

Jubilant Organosys is planning to expand its presence in the generic drugs space. The company plans to file applications to sell 10 off-pat...

Nexium is the second largest selling drug in the world and has annual sales of $5.5 billion in the US market alone.

Ranbaxy Laboratories has reached an out-of-court settlement to market the generic copy of an innovator drug worth over $1 billion in the US.

India’s largest drug-maker Ranbaxy has locked horns with the US-based world’s largest drug-maker Pfizer in 17 countries.

Ranbaxy Laboratories is considering setting up a special purpose vehicle (SPV) for launching a bid on Merck’s generic business. The SPV rou...